Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Cybin Inc. Common Shares (NY:CYBN)

7.735 -0.205 (-2.58%)
Streaming Delayed Price Updated: 12:36 PM EDT, Jul 7, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Cybin Inc. Common Shares

< Previous 1 2
...
12 13 14 15 16 17 18 19 Next >
PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Announces Key FDA Approvals, Participation in Psychedelics Conference
Via Investor Brand Network
Cybin Announces FDA Investigational New Drug and Institutional Review Board Approvals for a Co-Funded Phase 2 Clinical Trial to Treat Frontline Clinicians Experiencing COVID-Related Distress
From Cybin Inc.
Via Business Wire
Cybin to Participate in the H.C. Wainwright 2nd Annual Psychedelics Conference on December 6, 2021
From Cybin Inc.
Via Business Wire
PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Notes Adelia Milestone Achievements
Via Investor Brand Network
PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Awards Grant for Psychedelic Treatment Clinic to Benefit Underserved Communities
Via Investor Brand Network
Cybin Awards Grant for Psychedelic Treatment Clinic at Lenox Hill Hospital to Benefit Underserved Communities
From Cybin Inc.
Via Business Wire
Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Moves ‘One Step Closer’ to Creating Best Therapy for Mental Health
Via Investor Brand Network
PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Releases Q2 Financial Results, Business Highlights
Via Investor Brand Network
Topics Intellectual Property
Use of Ketamine for Mental Disorders Rising While New Therapies Emerge
Palm Beach, FL –November 17, 2021 – FinancialNewsMedia.com News Commentary – The uses of Ketamine for a variety of therapies are growing. An expanding number of clinics are offering ketamine infusion... 
Via FinancialNewsMedia
Cybin Inc. Reports its Second Quarter Financial Results and Recent Business Highlights
From Cybin Inc.
Via Business Wire
Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Launches Transformative Training Program for Psychedelic Facilitators
Via Investor Brand Network
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) to Present at Jefferies London Healthcare Conference
Via Investor Brand Network
PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) to Release Q2 2021 Financial Results, Host Call
Via Investor Brand Network
Cybin to Announce Second Quarter FY2021 Financial Results and Business Update on November 15, 2021
From Cybin Inc.
Via Business Wire
PsychedelicNewsBreaks – Cybin Inc.’s (NYSE American: CYBN) (NEO: CYBN) CYB003 Demonstrates Numerous Advantages over Oral Psilocybin for Treatment of Mental Health
Via Investor Brand Network
Cybin Announces Positive CYB003 Data Demonstrating Significant Advantages Over Oral Psilocybin for Treatment of Mental Health
From Cybin Inc.
Via Business Wire
PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Receives Schedule I Manufacturing License from DEA
Via Investor Brand Network
NetworkNewsAudio – Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) Offers Hope on the Smoking-Cessation Horizon
Via Investor Brand Network
Cybin Granted DEA Schedule I Manufacturing License
From Cybin Inc.
Via Business Wire
Increasing Prevalence of Depression & Mental Health Disorders Fueling Huge Growth in Psychedelic Drugs Market
Palm Beach, FL –November 4, 2021 – FinancialNewsMedia.com News Commentary – The pace of society’s change in attitude to the use of psychedelics has been amazing. It has gone from a “Born To Be Wild”,... 
Via FinancialNewsMedia
Topics Law Enforcement
PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Schedules R&D Briefing to Release Breakthrough Research Findings
Via Investor Brand Network
Cybin Hosting Research and Development Briefing on November 8, 2021
From Cybin Inc.
Via Business Wire
PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Unveils Psychedelic Facilitator Training Program Based on Groundbreaking Psychotherapy Approach
Via Investor Brand Network
Breaking the Habit: Psychedelic Stigma Fades as Research Points to Critical Use in Smoking Cessation and More
Via Investor Brand Network
Cybin Announces Launch of EMBARK Psychedelic Facilitator Training Program
From Cybin Inc.
Via Business Wire
Developments with Ketamine Psychotherapy Are Driving A Medical Revolution For Treating Mental Health Issues
Palm Beach, FL –October 28, 2021 – FinancialNewsMedia.com News Commentary – Psychedelic drugs such as psilocybin, LSD and MDMA have tremendous medical and commercial future potential… and for ketamine,... 
Via FinancialNewsMedia
Topics Death Law Enforcement
PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Announces FDA IND Authorization of Potentially Pivotal Study
Via Investor Brand Network
North America Continues Leading The Way In Psychedelic Wellness
Palm Beach, FL –October 26, 2021 – FinancialNewsMedia.com News Commentary – The global psychedelic drugs market remains at an early stage in its life cycle, with most companies currently developing... 
Via FinancialNewsMedia
Cybin Announces FDA Investigational New Drug Authorization of Cybin’s Sponsored Feasibility Study Using Kernel Flow Technology
From Cybin Inc.
Via Business Wire
Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Files Patent Application Amid ‘New Era’ of Psychedelic Medicine
Via Investor Brand Network
Topics Intellectual Property
< Previous 1 2
...
12 13 14 15 16 17 18 19 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.